- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07728513
Improving AI-Assisted Medical Diagnosis and Triage by the General Public
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
As large language models (LLMs) become widely accessible, a growing share of the public already turns to AI-powered chatbots for health-related information: surveys suggest that one in six American adults consults AI chatbots for health queries at least once a month. At the same time, diagnostic errors and misplaced triage decisions represent a persistent source of preventable patient harm globally [4]. This has prompted considerable interest in whether LLMs can serve as a reliable "front door" to the healthcare system for patients who lack immediate access to a clinician.
However, incidents involving misguided medical suggestions from LLMs to the general public such as fatal overdose and erroneous diagnosis leading to life-threatening treatment delay have been reported. A recent controlled study shows LLMs perform significantly worse for medical assistance in real-world settings compared to their performance on controlled benchmarks. Bean et al. [1] conducted a large preregistered study with 1,298 UK participants in which laypeople were assigned to receive assistance from one of three popular LLMs (GPT-4o, Llama 3, or Command R+) or to use a source of their choice when assessing ten standardized medical scenarios. Although the LLMs alone correctly identified relevant conditions in up to 94.9% of cases, participants using those same LLMs did so in fewer than 34.5% of cases, significantly worse than the group using their typical home resources (∼60%). Similarly, triage accuracy showed no signifcant difference between LLM users and controls, with an overall correct response rate of 43.0% across all groups. This poor performance can be linked to two main failure modes: users providing incomplete symptom information to the AI, and users failing to correctly interpret or act upon the LLM's output.
To address these failure modes, the study tests a new GPT-4o interface wrapped with a fixed system prompt. Rather than passively responding to whatever the user volunteers, the AI is instructed to ask clarifying questions to gather a proper clinical history before offering any medical suggestions. Once the model judges that enough information is gathered, it provides a structured, easy-to-read response detailing possible conditions, their likelihoods, and a clear triage recommendation.
The trial is structured as a two-arm, single-blind RCT. Both arms retain access to whatever assistance methods participants would normally use at home (e.g., web search), and both arms additionally get a GPT-4o-based LLM interface. The difference lies in which interface: the treatment arm receives the new interface described above, while the control arm receives a standard, unmodified GPT-4o interface with no special prompting. Participants are restricted to using the provided LLM interface (GPT-4o) only, and not other LLMs. AI-overview in web searches will be disabled through an extension. The trial utilizes ten previously validated clinical vignettes covering various medical urgencies, ranging from self-care routines up to ambulance-level emergencies, with each participant randomly assigned two of the ten. To achieve sufficient statistical power (accounting for within-participant clustering across those two responses), the target sample size is calculated at 220 total participants, split evenly with 110 individuals per arm.
The participant pool is drawn from the enrolled students and administrative staff at the Lahore University of Management Sciences (LUMS) in Pakistan. To ensure the sample consists strictly of laypeople, anyone currently enrolled in or who has completed a medical, nursing, or allied health professional degree is explicitly excluded from participating.
The study is driven by two co-primary hypotheses: participants with access to the new LLM interface will identify relevant medical conditions at a higher rate than participants using the standard LLM interface, and they will correctly assess the urgency of the medical scenarios at a higher rate. Accuracy is measured by comparing participant responses to a physician-generated gold-standard list using fuzzy matching, then analyzed via mixed-effects logistic regression with participant-level covariates and a Bonferroni-corrected significance threshold. The study also tracks secondary outcomes - self-reported confidence and time spent per scenario - and several exploratory analyses, including an LLM-alone benchmark, moderation by LLM experience, internet usage patterns, digital literacy, and scenario-level variation in accuracy.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Ihsan Ayyub Qazi, PhD
- Telefonnummer: +923233333766
- E-Mail: ihsan.qazi@lums.edu.pk
Studieren Sie die Kontaktsicherung
- Name: Ayesha Ali, PhD
- Telefonnummer: 04235608368
- E-Mail: ayeshaali@lums.edu.pk
Studienorte
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Rekrutierung
- Lahore University of Management Sciences
-
Kontakt:
- Ihsan Ayyub Qazi, PhD
- Telefonnummer: +923233333766
- E-Mail: ihsan.qazi@lums.edu.pk
-
Kontakt:
- Ayesha Ali, PhD
- Telefonnummer: 04235608368
- E-Mail: ayeshaali@lums.edu.pk
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Enrolled student or employed administrative staff at LUMS.
- 18 years of age or older.
- Able to read and understand English.
Exclusion Criteria:
- Individuals with any formal education or professional training in medicine, nursing, or any other healthcare profession.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment Arm (new GPT-4o Interface)
Participants can access any assistance methods they would typically employ (e.g., web search or health portals) in addition to a new LLM interface (based on GPT-4o) to complete medical scenarios.
The new LLM interface uses a fixed system prompt that (a) instructs the model to ask targeted clarifying questions before providing any diagnostic or triage suggestions, and (b) requires all final responses to follow a structured template listing: possible conditions, approximate likelihood of each, and a recommended triage with brief reasoning.
|
Participants can access any assistance methods they would typically employ (e.g., web search or health portals) in addition to a new LLM (GPT-4o) interface to complete medical scenarios.
The new LLM interface uses a fixed system prompt that (a) instructs the model to ask targeted clarifying questions before providing any diagnostic or triage suggestions, and (b) requires all final responses to follow a structured template listing: possible conditions, approximate likelihood of each, and a recommended triage with brief reasoning.
|
|
Placebo-Komparator: Control
Participants can use any assistance methods they would typically employ (e.g., web search or health portals) in addition to a standard LLM (GPT-4o) to complete medical scenarios.
AI-overview in web searches will be disabled via an extension.
They would not be allowed to access any LLMs other than the standard LLM interface.
|
Participants use any assistance methods they would typically employ at home (e.g., Google or health portals) in addition to a standard LLM (GPT-4o) to complete medical scenarios.
AI-overview in web searches will be disabled via an extension.
They would not be allowed to access any LLMs other than the standard LLM interface.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Urgency Assessment Accuracy
Zeitfenster: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
The primary outcome will be the percentage of correct urgency assessments, ranging from 0 to 100%, where higher scores indicate better urgency assessment (or triage) performance.
The rating which participants give for the urgency of each case, will be measured on a five-point scale: Self-care, Routine GP, Urgent Primary Care, Accident & Emergency, and Ambulance.
Responses will be compared against the gold-standard answers to produce an accuracy measure.
The primary outcome will be compared at the case-level between the randomized groups.
|
Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
|
Condition Identification Accuracy
Zeitfenster: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
The co-primary outcome is the Condition Identification Accuracy, which is the percentage of cases in which the condition was correctly identified, ranging from 0 to 100%., where higher scores indicate better medical condition identification performance.
Participants name all medical conditions they considered relevant to their decision.
A response is scored as correct for that scenario if at least one named condition matches the physician-generated gold-standard list of relevant conditions.
The co-primary outcome will be compared at the case-level between the randomized groups.
|
Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Self-Reported Confidence
Zeitfenster: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
Participants' self-reported confidence in their urgency assessments, measured using a scale ranging from 0 to 100.
|
Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
|
Time Spent
Zeitfenster: Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
The amount of time participants spend completing each medical scenario in milliseconds.
|
Assessed at a single time point for each case, during the scheduled diagnostic evaluation session, which takes place between 0-5 days after participant enrollment.
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Ayesha Ali, PhD, Lahore University of Management Sciences (LUMS)
- Studienstuhl: Ihsan Ayyub Qazi, PhD, Lahore University of Management Sciences (LUMS)
- Hauptermittler: Zafar Ayyub Qazi, PhD, Lahore University of Management Sciences (LUMS)
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AI-Assisted-Diag-Public789
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .